Design and baseline characteristics of the phase 3 ESSENCE trial of weekly semaglutide 2.4 mg in 800 participants with biopsy-proven MASH and fibrosis stage 2 or 3, with no efficacy results reported yet. PICO summary and expert commentary.
Browsing: GLP-1 Receptor Agonists
Clinical trial summaries for GLP-1 receptor agonists, including cardiovascular outcomes, glycaemic control, obesity, kidney outcomes, tolerability, and practice implications.
A post hoc analysis of SUSTAIN 6 suggesting once-weekly semaglutide lowered new-onset diabetic kidney disease in type 2 diabetes. PICO summary and expert commentary.
A phase 1 crossover study of the IcoSema fixed-ratio combination of insulin icodec and semaglutide reports unchanged icodec exposure but a higher, earlier semaglutide peak versus separate injections. PICO summary and expert commentary.
Post hoc analysis of the STEP 1, 2, 3, and 5 trials finds semaglutide 2.4 mg did not increase depression or suicidal ideation versus placebo in people without major psychopathology. PICO summary and expert commentary.
PIONEER 11 found that oral semaglutide monotherapy lowered HbA1c at all doses versus placebo in drug-naive, predominantly Chinese adults with type 2 diabetes, with weight reduction confined to the 7 mg and 14 mg doses. PICO summary and expert commentary.
A prespecified analysis of the FLOW randomised trial found once-weekly semaglutide reduced heart failure events and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
A prespecified mortality analysis of the SELECT trial found that semaglutide 2.4 mg lowered all-cause death in adults with obesity and cardiovascular disease but no diabetes. PICO summary and expert commentary.
A secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials shows semaglutide 2.4 mg improves symptoms, weight, and exercise capacity in obesity-related HFpEF consistently across baseline C-reactive protein strata. PICO summary and expert commentary.
Pooled patient-reported outcomes from the STEP 1-4 trials show semaglutide 2.4 mg improved physical functioning versus placebo over 68 weeks. PICO summary and expert commentary.
A prespecified analysis of the SELECT randomised trial showing sustained four-year weight loss with semaglutide versus placebo in adults with cardiovascular disease and obesity but no diabetes. PICO summary and expert commentary.